

For Public Release  
NZX Limited  
Wellington

19 May 2021

### **Cannasouth Appoints Experienced Head of Quality**

Cannasouth Limited (NZX: CBD) has appointed an experienced professional, Satish Nand, as Head of Quality for the Group.

Nand will be responsible for managing quality systems across the Cannasouth Group. He brings to Cannasouth more than 18 years of GMP regulated industry experience working with companies such as GMP Pharmaceuticals, Vitaco Health NZ, and Douglas Pharmaceuticals.

Cannasouth CEO Mark Lucas says Cannasouth has an existing team of high-caliber Quality and Regulatory professionals across the Group who have obtained commercial activity licences and submitted product assessment applications under the new Medicinal Cannabis Scheme. "This additional Head of Quality role is a key leadership role to support the journey towards validation and GMP certification stage of the Cultivation facility build project.

"New Zealand regulations require companies to operate to the highest pharmaceutical standards. To participate in the medicinal cannabis industry requires not only purpose-built facilities, but also professionals with expertise in key areas. Quality is one of those key areas.

"We believe we have the most complete team in New Zealand for a vertical medicinal cannabis company wanting to compete in the fast-growing global market."

Nand's first priority will be driving a groupwide action plan that ensures progress towards obtaining GMP and GACP certification across our cultivation and manufacturing sites.

Nand says "It's great to be joining Cannasouth at a time when the business is striding towards commercial manufacturing. My previous experience, combined with knowledge from within the existing team will help realise this milestone sooner. I am excited to be part of the team which will improve patients' quality of life with medicines that are produced to the highest quality standards."

Nand commences his role with Cannasouth on 21 June 2021.

-ENDS-

For further information visit [www.cannasouth.co.nz](http://www.cannasouth.co.nz) or contact:

**Mark Lucas**

CEO, Cannasouth Limited  
Email: [mark.lucas@cannasouth.co.nz](mailto:mark.lucas@cannasouth.co.nz)  
Mobile: 021 484 649

**Colin Foster**

CFO, Cannasouth Limited  
Email: [colin.foster@cannasouth.co.nz](mailto:colin.foster@cannasouth.co.nz)  
Mobile: 027 577 1498

**About Cannasouth Limited**

Cannasouth is a biopharmaceutical research and product development company based in the Waikato heartland of New Zealand. The Company has been established to focus on the development of the medicinally beneficial attributes of cannabinoid compounds such as CBD, THC and associated chemical structures that are produced by the cannabis plant. Our goal is the development of next-generation cannabinoid medicines that support patients' health outcomes and improve their quality of life. Our products will be under GMP using environmentally friendly methods without the use of harmful chemicals or solvents, ensuring patients are treated with pure cannabinoid therapeutic compounds of the highest quality. The Cannasouth group holds commercial medicinal cannabis licenses granted by the Medicinal Cannabis Agency for cultivation, possession to manufacture, and supply activities.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>